Eprosartan_Mesylate: profile and news

Dishman to expand EM capacity to 7.2mt  Jan 12, 2006
Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ... - Business Standard,

Kos Reports 49% Increase in Revenue to $179.4 Million, Earnings ...  Aug 4, 2005
In May 2005, the Company acquired from Biovail Corporation's affiliates an exclusive license to Teveten (eprosartan mesylate) and Teveten HCT (eprosartan ... - Business Wire (press release)

Kos Announces Strategic Commercialization and Research and ...  May 3, 2005
Pursuant to the agreements, Kos acquired Teveten (eprosartan mesylate), Teveten HCT (eprosartan mesylate/hydrochlorothiazide) and obtained exclusive sales and ... - Business Wire

Kos Enters Cardio Area, Gets Biovail Products For $104M  May 3, 2005
Teveten (eprosartan mesylate) was launched in 1998 by London-based GlaxoSmithKline plc (then SmithKline Beecham) and acquired by Biovail in 2002. ... - BioWorld Online (subscription)